48Hour Discovery is at the forefront of peptide drug discovery, utilizing advanced technologies to streamline the identification and optimization of therapeutic peptides. The company employs chemically modified phage display technology, which allows for a highly customizable approach to drug discovery across various medical indications. This innovative platform is supported by a diverse array of phage libraries, cutting-edge bioinformatics, and sophisticated screening methods, enabling 48Hour Discovery to rapidly advance drug leads with high affinity and specificity. Their comprehensive services encompass the entire drug discovery process, from inception through synthesis and validation, making them a valuable partner for both emerging biotech firms and established pharmaceutical companies.

In addition to their technological capabilities, 48Hour Discovery has secured a robust intellectual property portfolio through patents assigned from the University of Alberta, which enhances their competitive edge in the biotechnology sector. The company is particularly focused on developing radiopharmaceutical assets, aiming to revolutionize cancer treatment through non-invasive systemic approaches. With strategic partnerships and significant funding from initiatives like the Edmonton Edge Fund and the Alberta Cancer Foundation, 48Hour Discovery is well-positioned to accelerate its research and contribute to advancements in precision medicine, ultimately addressing unmet medical needs in oncology and beyond.

Canada

Founded in 2017, 48Hour Discovery (48HD) has a powerful technology platform for peptide-based drug discovery. We are reducing the cost, time, and risk of developing new therapies with our innovative target screening strategy to quickly identify the best and most promising drug leads. 

48Hour Discovery

Company Details